BDX Share Price Performance
AU$0.062
-0.05 (-46.09%)
Price AU$0.062
Share PriceAU$0.062
BDX Community Narratives
There are no narratives available yet.
Recent BDX News & Updates
No updates
BCAL Diagnostics Limited Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.022
- Gross Margin
- 100.00%
- Net Profit Margin
- -304.89%
- Debt/Equity Ratio
- 5.6%
BCAL Diagnostics Limited Competitors
About BDX
- Founded
- 2010
- Employees
- n/a
- CEO
- WebsiteView website
BCAL Diagnostics Limited, a screening and diagnostic company, engages in developing a novel blood screening test to improve the diagnosis and monitoring of breast cancer. It develops BREASTEST, a laboratory developed test or in-house in vitro diagnostic blood test. The company was incorporated in 2010 and is headquartered in Sydney, Australia.
Australian Market Performance
- 7 Days: 0.7%
- 3 Months: 7.6%
- 1 Year: 14.0%
- Year to Date: 6.4%
Over the last 7 days, the market has remained flat, with no particular sector making any big moves this week. More promisingly, the market is up 13% over the past year. As for the next few years, earnings are expected to grow by 11% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading